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Background: Although Ki-ras and TP53 mutations have probably been the genetic abnormalities
most exhaustively implicated and studied in colorectal cancer (CRC) progression, their significance
in terms of disease relapse and overall survival has not yet clearly been established.
Patients and methods: A prospective study was carried out on paired tumor and normal colon
tissue samples from a consecutive series of 160 previously-untreated patients, undergoing resective
surgery for primary operable sporadic CRC. Mutations within the TP53 (exons 5–8) and Ki-ras
(exon 2) genes were detected by PCR-SSCP analyses following sequencing.
Results: Mutation analyses of exons 5 to 8 of the TP53 gene showed mutations in 43% (68/160) of
the cases, while mutation analyses of exon 2 of the Ki-ras gene showed mutations in 46% (74/160)
of the cases. Multivariate analyses showed that clinical outcome were strongly associated with the
presence of specific TP53 mutations in L3 domain alone (only in DFS) or in combination with
specific Ki-ras mutations at codon 13.
Conclusion: Specific TP53 mutations in L3 domain alone (only in DFS) or in combination with
specific Ki-ras mutations at codon 13 are associated with a worse prognosis in sporadic CRC.
Introduction
Colorectal Carcinoma (CRC) represents a major public health
problem, especially in developed countries [1]. Numerous
studies have already defined the genetic mechanisms of the
adenoma-carcinoma sequence in CRC [2] and, although it has
been suggested that in CRC progression the accumulation of
multiple mutations is more relevant than the actual sequence
of events, it has also been reported that Ki-ras mutations
occur at the early stages of CRC development while TP53
mutations are usually predominant in advanced stages [3].
Ki-ras belongs to the ras gene family (H-, Ki- and N-ras)
and encodes a protein with a molecular weight of 21 000
(p21) which is located within the inner plasma membrane and
demonstrates GTPase activity and activation of gene products
[4]. Oncogenic mutations of Ki-ras are involved in 40% (20–
50%) of sporadic CRCs [5–7]. Most of the mutations (90%)
are found in codons 12 and 13; less frequently they may also
affect codon 61.
The TP53 tumor suppressor gene encodes a DNA sequence-
specific transcription factor, a 53-kDa nuclear phospho-protein
with multiple functions including gene transcription, DNA
synthesis and repair, apoptosis, and angiogenesis [8].
Mutations in the TP53 gene are among the most frequently
found genetic abnormalities in human cancers [9, 10]. In fact,
mutations of the TP53 gene have been observed in more than
50% of sporadic CRCs [11]. The majority of these, occur in a
highly conserved regions among species (area II, codons 112–
141; area III, codons 171–181; area IV, 234–258; area V
271–286) that codify for the protein core domain. Several
structural domains with distinct roles have been identified
within these regions: the L2 loop (codons 163–195), required
for the folding and stabilization of the central part of the
protein; the L3 loop (codons 236–251) and the LSH (L1 loop-
sheet-ahelix) motif (codons 273–286) within which at least
two residues (241, 248 and 273, 280 respectively) contact the
DNA directly [12].
Although a large number of primary sporadic CRC contain
a mutated Ki-ras and/or TP53 genes, their relationship to
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the development of a metastatic phenotype and hence to
patients’ outcome is still not clear [13–17]. However, TP53
and Ki-ras mutations affecting regions which are important for
particular functions of the proteins may have a stronger prog-
nostic impact. In fact, it has recently been observed that the
most frequent types of Ki-ras mutations in CRC are G! A
transition [18] and G! T transversion [19], that the presence
of a codon 12 glycine to valine mutation may predispose to
more aggressive biological behaviour in patients with advanced
CRC [20] and that specific codon 13 Ki-ras mutations are
predictive of clinical outcome in CRC patients, whereas codon
12 K-ras mutations are associated with a mucinous histotype
[21]. Moreover, it has been suggested that TP53 mutations in
exon 7 [22], codon 245 [23], conserved areas [24] and the L3
structural domain [25–26] were associated with more CRC
aggressive phenotype, presumably because these mutations
have a particularly strong negative effect on the biological
activity of the protein. Over the last few years, different studies
have simultaneously analyzed Ki-ras and TP53 genes point
mutations in CRC patients and their potential clinical
usefulness [17, 27–28] but, to our knowledge, no other study
has analyzed the prognostic role of specific Ki-ras and TP53
mutations.
The aim of our prospective study was to evaluate, in 160
patients who had undergone curative surgical resection for
primary sporadic CRC, whether specific TP53 and/or Ki-ras
genes mutations might have a particular prognostic signifi-
cance in CRC progression. For this reason, we performed a
multivariate analyses considering two different models in
which specific TP53 and /or specific Ki-ras are evaluated for
both distinct and combined variables.
Materials and methods
Patient features
A prospective study was performed on paired tumor and normal colon
tissue samples from a consecutive series of 160 previously untreated
patients, undergoing resective surgery for primary operable sporadic CRC
at a single institution (Department of Oncology, University of Palermo)
from January 1988 to December 1992.
Briefly, none of the patients had any history of previous neoplasias,
synchronous or metachronous CRC. This series of patients comprised 84
females and 76 males with a median age of 66 years (range 31–88).
A total of 137 patients were potentially cured by means of radical surgical
tumor resection with regional en bloc lymphadenectomy proximally up
to the origin of the vascular trunks. Twenty-three patients had either non-
radical surgery or distant metastasis.
All tumors were histologically confirmed to be colorectal adenocarci-
nomas. Patients with Dukes’ stage A and B sporadic CRC were treated
with surgery alone, whereas only 10 patients with Dukes’ stage C received
adjuvant chemotherapy with 5-FU, leucovorin and levamisole since in the
period previous to 1991 hardly any of the patients had received adjuvant
treatment. Patients with non-radical surgery and/or distant metastasis were
treated with 5-FU and leucovorin. Postoperatively, all patients were
checked at 3-monthly intervals for the first 2 years, at 6-monthly intervals
for the next 2 years, and annually thereafter. Written informed consent
was obtained from all patients included in this study.
Tissue handling
Multiple samples of the primary tumor tissue were taken from different
tumor areas (including the core and the invasive edge of the tumor).
Furthermore, multiple samples of normal mucosa (as confirmed by
histology) were taken from macroscopically uninvolved areas 20–40 cm
away from the tumor site, to be used as a control for biomolecular and
flow-cytometric analyses. The tissues were bisected, one half of each
sample was processed for pathological examination, and the remaining
half of the sample pool was immediately frozen and stored at 808C until
analyzed. The adequacy of the material was checked on frozen tissue
sections and only tissue samples with >80% tumor content were utilized
in subsequent biomolecular analyses. Evaluation of each biomolecular
sample was performed independently by researchers who had no knowl-
edge of the clinical data regarding the samples.
Detection of TP53 and Ki-ras gene mutations
High molecular weight genomic DNA was extracted as previously
described [29] from primary sporadic CRC and normal colon specimens.
Mutations within the TP53 (exons 5–8) and Ki-ras (exon 2) genes were
detected by PCR-SSCP (Single Strand Conformation Polymorphism) ana-
lyses following sequencing, performed as described previously [30]. The
quality and the concentration of the amplification products were verified
by 1.5% agarose gel electrophoresis and ethidium bromide staining.
100 mg aliquots of the amplified DNA fragments, purified and concen-
trated by filtration through Microcon 50 columns (Amicon, Beverly, MA)
were denatured and analyzed by SSCP analyses. DNA of normal colon tis-
sue from each patient was also amplified and run in parallel with matched
tumoral DNA samples on SSCP gels, to evaluate the occurrence of germ-
line mutations or polymorphisms. Individual ssDNA fragments with
shifted mobilities, compared to normal controls, were electroeluted from
polyacrylamide gel, reamplified and subjected to automated sequencing by
3100 Genetic Analyzer (Applied Biosystems, Foster City, CA) as
described previously [30].
Statistical analyses
Fisher’s exact test (StatXact Turbo, Cytel Software Corporation,
Cambridge, MA, USA) was used to evaluate the associations between
biological variables. The relationship of different prognostic variables to
disease-free survival (DFS) and overall survival (OS) was assessed
univariately by means of the Kaplan and Meier method. Survival time was
calculated from the date of surgery to the date of death (cancer-related
causes) or last follow-up, with times censored for patients dying of causes
unrelated to CRC and those surviving. DFS was measured from the day of
primary surgery to the date of the first relapse (locoregional or metastatic).
Significant differences among survival curves were checked by the log-
rank test and Wilcoxon test, or a test for trend when appropriate.
Multivariate analyses was carried out by means of Cox proportional
hazards model, using a backward procedure [24]. P values <0.05 were
considered significant.
Results
Mutation analysis of TP53 gene
Mutation analysis of exons 5 to 8 of the TP53 gene showed
mutations in 43% (68/160) of the cases (Figure 1). In parti-
cular, 84 TP53 mutations were identified in 68 of the 160
screened CRCs, and sequence data were obtained for 81. Of
the 84 mutations, 19% (16 of 84) were in exon 5, 32% (27 of
84) in exon 6, 36% (30 of 84) in exon 7 and 13% (11 of 84)
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in exon 8. Fourteen tumor samples presented two (9 in the
same exon and 3 in two different exons) or three (2 in two
different exons) different TP53 mutations. Nineteen of the 81
sequenced mutations (23%) were found to be frameshifts (15
microdeletions and 4 microinsertions) whereas 62 (77%) were
single-nucleotide substitutions. 82% (51 of 62) of the latter
were mis-sense (45 of 62) or nonsense (6 of 62) mutations,
while silent mutations were found in 11 cases (9 of them
being in codon 213, a previously identified site of polymorph-
ism). Moreover, transitions (81%, 50 of 62) were far more fre-
quent than transversions (19%). No germ-line mutations were
found indicating that in every case the change was somatic.
Tumors with TP53 mutations were classified into two groups:
18/68 cases (26%) with mutations of the L3, 11/68 cases
(16%) with mutations of the LSH motif and 39/68 cases
(58%) with mutations outside L3 and LSH. Since silent
mutations do not determine any amino acid change in the pro-
tein, they have been included in the wild type group for stat-
istical analyses.
Mutation analyses of the Ki-ras gene
Mutation analyses of exon 2 of the Ki-ras gene showed
mutations in 46% (74/160) of the cases (Figure 1). Eighty
Ki-ras mutations were identified in 74 of the 160 screened
CRCs. Of the 80 mutations, 57% (46 of 80) were found in
codon 12, and 43% (34 of 80) in codon 13, (68/74 tumors pre-
sented single mutations, 3/80 a double mutation in codon 12,
and 3/80 a mutation in codon 12 and one in codon 13). The
most frequent mutation in codon 12 was GGT to GAT
(Gly!Asp), which was observed in 17/46 cases (37%).
The most frequent mutation in codon 13 was GGC to GAC
(Gly! Asp) which was detected in 32/34 cases (94%).
Overall, transitions (70% 56 of 80) were the predominant
alteration. No germ-line mutations were found indicating that
in every case the change was somatic.
254 36
T M
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Figure 1. (a) SSCP analyses of exon 7 of the TP53 gene, amplified from
colorectal carcinoma and mucosa genomic DNA of 1 patients (254). The
extra bands visualized in lanes 2 correspond to ssDNA molecules
harbouring mutations in codon 248 (CGG! TGG); (b) SSCP analyses of
exon 1 of the k-ras gene, amplified from colorectal carcinoma and mucosa
genomic DNA of 1 patients (36). The extra bands visualized in lanes 2
correspond to ssDNA molecules harbouring mutations in codon 12
(GGT! GTT).
Table 1. Patient characteristics (n= 160)
Characteristic No. Pts
Sex:
Male 76
Female 84
Age:
<55 29
55–75 96
>75 35
Site:
Proximal tumor 31
Distal tumor 129
Tumor size (cm):
<_ 5 60
>5 100
Dukes’ Stage:
A 40
B 51
C 41
D 28
Node status:
Negative 101
Positive 59
Tumor growth:
Expansive 20
Infiltrative 140
Tumor grade:
Well differentiated (G1) 23
Mod differentiated (G2) 104
Poorly differentiated (G3) 33
Tumor type:
Adenocarcinoma NOS 137
Mucinous 23
Lymphoemative invasion:
None 45
Present 115
Lymphocytic infiltrate:
Prominent 48
Non-prominent 112
Surgery:
Curative resection 137
Non curative resection 23
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Uni- and multivariate analyses of prognostic factors
The median follow-up time in our study group was 71
months (range 34–115 months). The median survival of the
whole group was 43 months. At univariate analyses, distal
cancers, infiltrative tumor growth, advanced Dukes’ stage,
node status positive, lymphohematic invasion, DNA-aneu-
ploidy, high SPF, the presence of TP53 mutations in L3, Ki-
ras mutations in codon 13 and TP53 and/or Ki-ras in L3
and/or in codon 13, proved to be significantly related to
quicker relapse whereas these same factors, and in addition
non-curative resection were significantly related to shorter
overall survival (Table 2).
At multivariate analyses we considered a model with TP53
and/or Ki-ras as a distinct variable (Model DV) and a model
with TP53 and/or Ki-ras as a combined variable (Model CV)
(Table 3). Multivariate analyses in both models was adjusted
for DFS according to Dukes’ stage, lymphohematic invasion,
DNA-aneuploidy and high SPF; while for OS according to
Dukes’ stage, surgical resection, DNA-aneuploidy and high
SPF.
The major significant predictors for both disease relapse
and death were TP53 mutations affecting the L3 loop, while
Ki-ras mutations affecting codon 13 were the only indepen-
dent factors for death (Table 3). Moreover, when the TP53
and Ki-ras mutations were considered together, mutations
affecting p53 in the L3 loop and/or Ki-ras in codon 13 were
independent factors for both disease relapse and death. Discussion
Although Ki-ras and TP53 mutations have probably been the
genetic abnormalities most exhaustively implicated and
studied in sporadic CRC progression [3], their significance in
terms of disease relapse and overall survival has not yet been
clearly established. This variability can be explained by sev-
eral factors, such as the different methods used to assess TP53
or Ki-ras mutations (SSCP; DGGE, Denaturing Gradient Gel
Electrophoresis; TGGE, Temperature Gradient Gel Electro-
phoresis; direct sequencing), the type of tumor storage (fresh/
frozen tissue and paraffin embedded blocks) and an intrinsic
tumoral heterogeneity that might mask, mainly in the cases
with Dukes’ stages A-B CRC, the lower percent of single
cells with these genetic alterations. Furthermore, the specific
features of the patient cohorts enrolled in the study may give
rise to artifacts in mutational and, thus, in statistical analyses.
For example, it has been reported that specific Ki-ras
mutations in codon 12 were associated with mucin histotype
[21], while it is well known that patients at an advanced
Dukes’ stage (C and D) generally present a higher rate of
TP53 mutations [31, 32]. Another source of discrepancy con-
cerning TP53 mutations and prognosis of CRC may be related
to differences between immunohistochemical and molecular
genetic analysis of TP53. Several factors have been taken into
consideration as an explanation for the fact that TP53
mutations are mostly mis-sense leading to a protein with a
prolonged half life which makes it immunohistochemically
detectable only in 50–80% of cases [33]. Finally, it should be
Table 3. Multivariate disease-free and overall survival analyses
DFS (n= 138) OS (n= 160)
HR (95%CI) P value HR (95%CI) P value
1. Model DVa
P53:
L3 vs no mutation 2.14
(1.06–4.32)
<0.05 2.26
(1.21–4.21)
<0.05
Ki-ras:
Mut. in codon 13
vs no mutation
1.86
(1.10–3.17)
<0.05
2. Model CVb
p53 and/or Ki-ras:
No mutations 1 1
Mutations in L3
and/or codon13
vs no mutations
2.42
(1.32–4.43)
<0.01 2.24
(1.30–3.84)
<0.01
amodel with TP53 and/or Ki-ras as Distinct Variable;
bmodel with TP53 and/or Ki-ras as Combined Variable; Pts: Patients; DFS:
Disease Free Survival; OS: Overall Survival; HR: Hazard Ratio;
CI: Confidence Interval.
Multivariate analyses was adjusted for DFS according to Dukes’ stage,
lymphatic invasion, DNA-ploidy and SPF; while for OS according to
Dukes’ stage, surgical resection, DNA-ploidy and SPF. Mutations in codon
12, outside L3 and mutations outside L3 and/or codon13 are not indepen-
dent variables for DFS and OS both in DV and CV models.
Table 2. Univariate (distribution of pts only for the significant TP53
and/or Ki-ras variables) disease-free and overall survival analyses
No.
Pts
DFS
(%)
5 yrs
P No.
pts
OS
(%)
5 yrs
P
aTP53
No. mutations 87 56 100 49
Mutations outside LSH/L3 26 27 29 34
Mutations in LSH 9 33 11 27
Mutations in L3 13 15 18 11
bKi-ras
No mutations 77 53 86 47
Mutations in cod.12 34 56 40 47
Mutations in cod. 13 27 22 34 18
TP53 and/or Ki-ras
No mutations 54 60 60 54
Mut. Outside L3 and/or cod.13 46 52 53 45
Mutations in L3 and/or cod.13 36 22 46 17
a All mutation subgroups are compared with patients with no mutations
(wild type TP53).
b All mutation subgroups are compared with patients with no mutations
(wild type Ki-ras).
Pts: Patients; DFS: Disease-Free Survival; OS: Overall Survival.
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considered that the majority of the studies have used a retro-
spective design, so it has not been possible to draw final
recommendations about the application of such aberrations as
prognostic factors.
In the present study, we have prospectively evaluated the
prognostic value of Ki-ras and TP53 gene mutations detection
in a series of 160 patients with sporadic CRC, taking special
care in using a methodologic approach that is suitable for
reproduction in other laboratories. In accordance with several
other reports [11, 26, 32], 43% of all the mutations observed
in our series (68/160) were found in a region of the gene
which includes two important regions for TP53 binding to
DNA. One of these contains the amino acids needed for DNA
interaction, in particular those which are part of the L3 Zinc-
binding domain and of the LSH motif. In our own series, 26%
(18/68) of the mutations occurred in L3 and 16% (11/68)
in LSH, in accordance with the results reported by
Borresen-Dale [25].
For Ki-ras gene, we found a mutation rate in exon 2 of 46%
(74/160) for a total of 80 mutations: 57% (46/80) in codons
12 and 43% (34/80) in codon 13; this is hardly surprising
since most of the mutations found in human tumors involve
these two codons, coding for two adjacent glycines located in
proximity of the catalytic site of RAS. This means that differ-
ent Ki-ras mutations resulting in the incorporation of different
amino acids at these positions leads, albeit to a different
degree, to a reduction of the intrinsic GTPase activity of RAS.
In accordance with several other studies [13–21] these results
show that not all mutations are equal and that different muta-
tional types may can confer different biological properties.
Our report showed that specific TP53 in the L3 domain
and/or specific Ki-ras mutations at codon 13 are strong prog-
nostic indicators of worse survival, while only specific TP53
in L3 domain, alone or in combination with Ki-ras mutations
at codon 13, were an independent prognostic variable of DFS
in pts with primary sporadic CRC. These results suggest that
specific Ki-ras mutations in codon 13 have an effect on DFS
only when the mutation in the L3 domain of TP53 gene is
present. These findings also show that specific TP53 in L3
domain and Ki-ras mutations at codon 13 maintain their
predictive role even the presence of established traditional
prognostic variables such as Dukes’ stage, lymphatic invasion
or surgical resection.
In conclusion, we have provided evidence that specific TP53
and Ki-ras mutations have a divergent effect on the structure,
stability and function of the protein. In the analyses of the prog-
nostic value of Ki-ras and TP53 on sporadic CRC, the type of
mutations and its effect on biological function should be con-
sidered. Multivariate analyses showed that clinical outcome
were strongly associated with the presence of specific TP53
mutations in L3 domain alone (only in DFS) or in combination
with specific Ki-ras mutations at codon 13. Unfortunately, to
our knowledge, no other study has analyzed the prognostic role
of specific Ki-ras and TP53 mutations in CRC progression. If
our results on these biological indicators (specific TP53
mutations in L3 domain and/or Ki-ras mutations at codon 13)
are confirmed by large prospective studies, it will be possible
to provide additional and important useful information for
prognosis and a rational basis for the development of more
specific clinical treatments (more radical surgery, and/or adju-
vant chemotherapy or radiotherapy). In particular, efforts
should therefore be directed towards subsets of sporadic CRC
patients with a high risk of relapse or death, especially those
with Dukes’ stages B (Astler-Coller B2) and C.
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